Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10528926		
Filing Date		2005-03-23		
First Named Inventor Ande		rsen et al.		
Art Unit		1761		
Examiner Name	NYA			
Attorney Docket Number		GRP-0101		

Patent Number add additional U.S. Pater Publication Number 20050244538		Publication Date	Name of Patentee or Applicant of cited Document lease click the Add button. CATION PUBLICATIONS Name of Patentee or Applicant of cited Document	Pages Columns Lines where Relevant Passages or Relevant Figures Appear Add Semove Pages Columns Lines where Relevant Passages or Relevant Figures Appear
Publication Number	U.S.P	Publication Date	Name of Patentee or Applicant	Remove Pages, Columns, Lines where Relevant Passages or Relevant
Publication Number	U.S.P	Publication Date	Name of Patentee or Applicant	Remove Pages, Columns, Lines where Relevant Passages or Relevant
Publication Number	Kind	Publication Date	Name of Patentee or Applicant	Pages,Columns,Lines where Relevant Passages or Relevant
Publication Number		Date		Relevant Passages or Relevant
20050244538				
		2005-11-03	Andersen et al.	
2 20060051455 2006-03-09		Andersen et al.		
20060099300		2006-05-11	Andersen et al.	
20060121156		2006-06-08	Andersen et al.	
20060147580		2006-07-06	Nissen et al.	
a	20060121156 20060147580	20060121156 20060147580	20060121156 2006-06-08 20060147590 2006-07-06 dd additional U.S. Published Application citatio	20060121156 2006-06-08 Anderson et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Examiner Cite Foreign Document

A

E

Country

pplication Number		10528926		
ling Date		2005-03-23		
irst Named Inventor Ander		rsen et al.		
rt Unit		1761		
xaminer Name	NYA			
Manager Davids Monthles		GRR 0404		

Name of Patentee or

Date Considered

Pages, Columns, Lines

where Relevant

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	Ts	
	1								
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(e), volume-issue number(s), publisher, city and/or country where published.							Τs	
	1	W00056281 Publication Date 2002-05-06; "Composition for medicated chewing gums process for manufacturing the same and tablets so obtained" (Abstract Only)							
	2	J. Dent. Res. Vol. 28, No. 2; pages 160-171; April 1949							
	Application Serial Number 10/528,927 Filed December 16, 2006; Andersen et al.; "Biodegradable chewing gum comprising at least one high molecular weight biodegradable polymer" (available in IFW)								
	4	Application Serial Num	ber 10/529,137 Fil	ed Septe	ember 6, 2005;	Andersen et al.; "Gum base	" (available in IFW)		
If you wis	h to a	dd additional non-pate	nt literature docu	ment cit	tation informat	tion please click the Add	button Add	_	

Kind Publication

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached

FYAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor		10528926	
		2005-03-23	
		rsen et al.	
		1761	
		GRP-0101	

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sec 37 CFR 197(eV1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Roberta L. Pelletier/	Date (YYYY-MM-DD)	2006-07-26
Name/Drint	Deborte I. Dellator	Registration Number	46372

This collection of information is required by 3 T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3 T CPR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Operatment of Comments. P. D. 68. 1430, Alexandria, V.S. 2311.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2311.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.